Current Report Filing (8-k)
July 03 2018 - 2:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): July 1, 2018
Rennova
Health, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-35141
|
68-0370244
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
400 S. Australian Avenue, Suite 800, West Palm Beach,
Florida
|
33401
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(561)
855-1626
|
(Registrant’s
Telephone Number, Including Area Code)
|
|
|
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02.
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
The Board of Directors
of Rennova Health, Inc. (the “Company”) appointed Marlene McLennan as our Chief Financial Officer effective
July 1, 2018. Seamus Lagan, our Chief Executive Officer, had also been serving as interim Chief Financial Officer.
Ms. McLennan, 47,
has been Vice President of Finance of the Company since April 2, 2018. Previously, she served as Chief Financial Officer
of Medbridge Healthcare LLC, a leading provider of sleep laboratory management services and sleep therapy, from June 2017 to March
2018. Ms. McLennan, from February 2016 to April 2017, was the Chief Financial Officer of Barnes Healthcare Services, one of
the largest privately-owned home care companies in the country. From May 2015 to January 2016, she served as the Chief Financial
Officer of Cascadia Behavioral Healthcare, a 501(c)(3) not-for-profit organization in the behavioral and residential health
arena. Ms. McLennan also was the Chief Financial Officer of Monroe County Hospital, a comprehensive healthcare system serving
Monroe County and surrounding areas in Georgia, from January 2012 to February 2015.
Ms.
McLennan has no family relationship with any of the executive officers or directors of the Company. There are no arrangements
or understandings between Ms. McLennan and any other person pursuant to which she was appointed as an officer of the Company.
A
copy of the press release issued by the Company announcing Ms. McLennan’s appointment is attached hereto as Exhibit 99.1
and is incorporated by reference herein.
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: July 3, 2018
|
RENNOVA HEALTH, INC.
|
|
|
|
|
By:
|
/s/ Seamus Lagan
|
|
|
Seamus Lagan
|
|
|
Chief Executive Officer
|
|
|
(principal executive officer)
|